Esperanza Cañas‐Ruano

ORCID: 0000-0002-4651-7545
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • HIV-related health complications and treatments
  • HIV Research and Treatment
  • HIV/AIDS drug development and treatment
  • HIV/AIDS Research and Interventions
  • Viral-associated cancers and disorders
  • COVID-19 diagnosis using AI
  • Herpesvirus Infections and Treatments
  • COVID-19 and healthcare impacts
  • Lymphoma Diagnosis and Treatment
  • COVID-19 Clinical Research Studies
  • Bone and Joint Diseases
  • Emergency and Acute Care Studies
  • Systemic Lupus Erythematosus Research
  • Ultrasound in Clinical Applications
  • HIV, Drug Use, Sexual Risk
  • Hepatitis C virus research
  • MicroRNA in disease regulation
  • SARS-CoV-2 and COVID-19 Research
  • Long-Term Effects of COVID-19
  • Poxvirus research and outbreaks
  • Hepatitis B Virus Studies
  • Mitochondrial Function and Pathology
  • Aortic Thrombus and Embolism
  • CNS Lymphoma Diagnosis and Treatment
  • Lipid metabolism and disorders

Hospital Del Mar
2022-2025

Hospital Universitario de La Princesa
2025

Universidad Autónoma de Madrid
2025

Instituto de Salud Carlos III
2024

Hospital del Mar Research Institute
2022-2023

Vall d'Hebron Hospital Universitari
2020-2023

Parc de Salut
2023

Municipal Institute for Medical Research
2023

Vall d'Hebron Institut de Recerca
2020-2022

Universitat Autònoma de Barcelona
2019-2022

Natàlia Casamitjana Andrea Alemany Michael Marks Jezer I Lezama Mora Juan Carlos Rodríguez‐Aldama and 95 more Mayara Secco Torres Silva Ever Arturo Corral Herrera Brenda Crabtree‐Ramírez José Luís Blanco Nicolò Girometti Valentina Mazzotta Aniruddha Hazra Macarena Silva Juan José Montenegro-Idrogo Kelly A. Gebo Jade Ghosn María Fernanda Peña Vázquez Eduardo Matos Prado Uche Unigwe Judit Villar-García Noah Wald‐Dickler Jason Zucker Roger Paredes Alexandra Calmy Laura Waters Cristina Galván‐Casas Sharon Walmsley Chloe Orkin Viviana Leiro Lucila Marchetta Patricia Fernandez Pardal María Inés Figueroa Pedro Cahn Katharina Grabmeier‐Pfistershammer Agnès Libois Laurens Liesenborghs Beatriz Grinsztejn Mauro Schechter Alberto dos Santos de Lemos Alvaro Furtado Costa Simone Queiroz Rocha José Valdez Madruga Darrell H. S. Tan Sharmistha Mishra Shreya Shah Camila Jorquera Alberto Castillo Mauricio Carrión Nelson Salas Romain Palich Valérie Pourcher Emma Rubenstein Pascal Migaud Christoph Boesecke Christian Hoffmann Konstantinos Protopapas Silvia Nozza Anna Maria Cattelan Cristina Mussini Antonella d’Arminio Monforte Raúl Adrian Cruz Flores Edgar Pérez‐Barragán Alma Leticia Rodríguez Guzmán Dimie Ogoina Nneka Marian Chika-Igwenyi Chizaram Onyeaghala Jenny Valverde López Angelica García Tello María Ubals Martí Vall Adrià Mendoza Clara Suñer Bonaventura Clotet Jordi Bechini José Antonio Lepe Ma Dolores Navarro-Amuedo José I Bernadino Alba Català Eloy José Tarín Vicente Borja González Rodríguez Sergi Rodríguez-Mercader Francisca Sánchez-Martinez Esperanza Cañas‐Ruano Laura Parra‐Navarro Finn Filén Carmen Tallón de Lara Dominique L. Braun Vanja Piezzi M. Burkhard Helen Kovari Anja Mönch Jake Dunning Pedro Simoes Achyuta Nori Sarah S. Keegan John Thornhill Vanessa Apea Teymur Noori Joyce Jones Seth Judson

10.1016/s0140-6736(23)00273-8 article EN The Lancet 2023-02-22

The objective of this study was to assess the effect that triple therapy (anticoagulation plus CS plasma exchange and/or IVIGs) has on mortality risk patients with catastrophic APS (CAPS) included in CAPS Registry.Patients from Registry were grouped based their treatments: therapy; drugs but different combinations; and none treatments therapy. primary endpoint all-cause mortality. Multivariate logistic regression models used compare between groups.The cohort 525 episodes accounting for 502...

10.1093/rheumatology/key082 article EN Lara D. Veeken 2018-03-09

Abstract Purpose This study aims to evaluate the association between psychiatric disorders and diabetic ketoacidosis (DKA) in patients with type 1 diabetes (T1D) treated at a tertiary care hospital. Methods A propensity score-matched case-control was conducted, comprising total sample of 194 participants (97 DKA cases 97 controls without DKA). Comprehensive data were collected on clinical, anthropometric, socioeconomic characteristics, classified according international standards. Results...

10.1007/s12020-024-04146-y article EN cc-by Endocrine 2025-01-24

We investigated the efficacy of dolutegravir/lamivudine for maintenance treatment people with HIV and previous lamivudine resistance. Open-label, single arm, multicentric clinical trial including virologically suppressed PWH historical resistance (confirmed by genotypic testing or suspected based on history), no integrase CD4+ >200 cells/mm3 whose ART was changed to if M184V/I mutation not detected in baseline proviral DNA population sequencing. Proviral next-generation sequencing (NGS)...

10.1093/cid/ciaf100 article EN Clinical Infectious Diseases 2025-03-04

Background The impact of tenofovir disoproxil fumarate (TDF) antiretroviral (ART) regimens on bone health has been characterized mostly by mineral density (BMD), but recently also quality (BQ). aim this pilot study is to assess the changes in BMD and BQ after switch from TDF alafenamide (TAF) ART. Methods HIV individuals receiving TDF-based ART were randomized Bictegravir-TAF-Emtricitabine or remain same regimen. At baseline 24-weeks randomization, participants underwent (BMD) DXA assessment...

10.3389/fendo.2023.1076739 article EN cc-by Frontiers in Endocrinology 2023-03-27

This real-world study compared the safety and effectiveness of Dolutegravir/lamivudine (D/L) Bictegravir/Emtricitabine/Tenefovir alafenamide (B/F/T) switch therapy regimens for people living with HIV (PLWH).The retrospective conducted from April 2019 to November 2022, included PLWH < 50 copies/mL HIV-RNA prior recruitment who initiated either D/L or B/F/T switching therapy. The primary objective was evaluate treatment discontinuation rates; virologic outcomes were also evaluated.690...

10.1080/25787489.2023.2239564 article EN cc-by-nc HIV Research & Clinical Practice 2023-07-26

Abstract Purpose To design a randomized clinical trial to assess the efficacy and safety of favipiravir in patients with COVID-19 disease pneumonia. Methods A randomized, double blind, placebo-controlled pneumonia was conducted three Spanish sites. Randomization 1:1 or placebo (in both groups added Standard Care) performed treat The primary endpoint “time improvement,” measured as an improvement for ≥ two categories on 7-point WHO ordinal scale up 28 days' time frame. Results Forty-four were...

10.1186/s41479-023-00124-6 article EN cc-by Pneumonia 2024-02-25

To compare clinical characteristics, outcomes, and resource consumption of patients with coronavirus disease 2019 (COVID-19) seasonal influenza requiring supplemental oxygen.Retrospective cohort study conducted at a tertiary-care hospital. Patients admitted because between 2017 2019, or COVID-19 March May 2020 oxygen were compared. Primary outcome: 30-day mortality. Secondary outcomes: 90-day mortality hospitalization costs. Attempted sample size to detect an 11% difference in was 187 per...

10.1093/cid/ciac314 article EN Clinical Infectious Diseases 2022-04-19

Abstract Objective The HIV infection is a chronic disease that causes neurocognitive impairment (NI) and has been related with early development of frailty. We aimed to study the main risk factors for disorders frailty in older adults. Materials methods Cross-sectional 40 individuals than 65 years under antiretroviral therapy Hospital del Mar (Barcelona) recruited between November 2019 October 2020. Data obtained through clinical scores blood sample evaluate NI analyzed non-parametric tests...

10.1186/s40001-022-00639-6 article EN cc-by European journal of medical research 2022-02-02

Abstract People living with human immunodeficiency virus (HIV) are the individuals most affected by current Monkeypox outbreak that was first announced in May 2022. Here we report Pan‐pox‐specific T‐cell responses a cohort of HIV‐1‐infected after receiving nonreplicative, attenuated smallpox vaccine JYNNEOS from Bavarian Nordic. Intradermal (i.d.) and subcutaneous (s.c.) vaccination safe without major side effects. Dose‐sparing i.d. superior to s.c. promoted polyfunctionality, expression...

10.1002/jmv.29317 article EN cc-by Journal of Medical Virology 2023-12-27

Objectives The aim of the study was to investigate dynamics cytomegalovirus (CMV) replication and CMV‐specific immune response recovery after antiretroviral treatment (ART) initiation in patients with advanced HIV infection. Methods A prospective observational infection CD4 counts &lt; 100 cells/µL carried out (September 2015 July 2018). viral load (VL), count CMV VL were determined by quantitative polymerase chain reaction (PCR) at baseline 4, 12, 24 48 weeks, QuantiFERON‐CMV assay weeks....

10.1111/hiv.13115 article EN HIV Medicine 2021-05-17

Introduction. Long-term non-progressors (LTNPs) are HIV-infected individuals (HIV+) whose viral replication is controlled. However, these experience complications associated with HIV, among them, bone remodeling impairment. This study aims to perform a comprehensive health assessment and its association the inflammatory status of HIV+ LTNPs. A cross-sectional was conducted comparing strength components (bone mineral density tissue quality) between age-, sex-, comorbidities-matched groups...

10.3390/jcm11102927 article EN Journal of Clinical Medicine 2022-05-22

The objective was to compare clinical characteristics, outcomes, and economic differences in complicated urinary tract infections (cUTI) caused by extensively drug-resistant Pseudomonas aeruginosa (XDR P. aeruginosa) extended-spectrum beta-lactamase-producing Klebsiella pneumoniae (ESBL-K. pneumoniae). A retrospective study conducted at a tertiary care hospital. Patients with XDR ESBL-K. cUTIs were compared. primary outcome failure day 7 the end of treatment (EOT). Secondary outcomes: 30-...

10.3390/antibiotics11111511 article EN cc-by Antibiotics 2022-10-29

We evaluated the impact of hepatic steatosis-insulin resistance (HS-IR) and liver fibrosis (LF) on type 2 diabetes mellitus (DM2) using triglyceride-glucose (TyG) Fibrosis-4 (FIB-4). The incidence DM2 was 12.9 [95% confidence interval (CI), 16.9–9.7] 9.8 (95% CI, 6.9–13.6) per 1000 person-years in HS-IR LF. prevalence significantly lower at 12 24 months with TDF + (3TC or FTC) RPV [hazard ratio (HR) 0.5 0.3–0.8], P &lt; 0.01 months; 0.6 [0.4–0.9], = months].

10.1097/qad.0000000000004008 article EN AIDS 2024-10-30

Abstract Introduction People with HIV (PWH) poor immune response despite adequate antiretroviral treatment (ART) are susceptible to non-AIDS-related health issues. This study seeks evaluate bone quality in immunological nonresponders (INRs) comparison those proper (IRs) using vivo microindentation quantify quality, addition conventional mineral density (BMD) evaluations. Methods A cross-sectional was conducted at Hospital del Mar Barcelona from January 2019 June 2023. Participants were...

10.1210/clinem/dgae786 article EN publisher-specific-oa The Journal of Clinical Endocrinology & Metabolism 2024-11-11
Coming Soon ...